Compare $ALGS vs $ATNM | Chartloom

Compare

$ALGS vs $ATNM

Aligos Therapeutics Inc · Actinium Pharmaceuticals Inc

ALGS

Aligos Therapeutics Inc

ATNM

Actinium Pharmaceuticals Inc

Compare $ALGS vs $ATNM

Comparing Aligos Therapeutics Inc and Actinium Pharmaceuticals Inc

ALGSAligos Therapeutics Inc

ATNMActinium Pharmaceuticals Inc

ALGSAligos Therapeutics Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.83x

Rev growth (TTM)

893.0%

YTD performance

-41.5%

52W performance

-46.2%

FCF yield

-286.0%

ATNMActinium Pharmaceuticals Inc

Market cap

$35M

P/E (TTM)

3.06x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.7%

52W performance

-28.6%

FCF yield

-67.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALGS

ATNM

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

ATNM

Actinium Pharmaceuticals Inc

Market Cap

ALGS$33M

ATNM$35M

Enterprise Value

ALGS$3M

ATNM$-2M

Price

ALGS$5.34

ATNM$1.10

P/E Ratio

ALGSN/A

ATNM3.06x

P/S Ratio

ALGS1.05x

ATNM0.98x

EV/Sales

ALGS0.09x

ATNM-0.06x

EV/EBITDA

ALGS0.00x

ATNM-0.20x

P/B Ratio

ALGS1.09x

ATNM1.21x

P/FCF Ratio

ALGSN/A

ATNMN/A

EV/FCF

ALGS-0.03x

ATNM0.08x

PEG Ratio

ALGSN/A

ATNMN/A

Forward P/E (NTM)

ALGSN/A

ATNMN/A

Forward P/S (NTM)

ALGS4.83x

ATNMN/A

Revenue (TTM)

ALGS$32M

ATNM$35M

Revenue Growth (YoY)

ALGS893.0%

ATNMN/A

Forward Rev Growth

ALGS-84.9%

ATNM-0.2%

Gross Margin (TTM)

ALGS0.0%

ATNM0.0%

Operating Margin (TTM)

ALGS0.0%

ATNM62.3%

EBITDA Margin (TTM)

ALGS-247.2%

ATNM27.9%

Net Margin (TTM)

ALGS-241.0%

ATNM32.2%

FCF Margin (TTM)

ALGS-299.9%

ATNM-66.2%

Net Income (TTM)

ALGS$-76M

ATNM$11M

FCF (TTM)

ALGS$-95M

ATNM$-23M

EPS (TTM)

ALGS-$7.28

ATNM$0.36

ROE (TTM)

ALGS-16072.0%

ATNM83.4%

ROA (TTM)

ALGS-9230.0%

ATNM23.4%

ROIC (TTM)

ALGS-16035.0%

ATNM83.4%

Cash

ALGS$30M

ATNM$36M

Debt

ALGS$64K

ATNM$5K

Net Cash/Debt

ALGS$30M

ATNM$36M

Current Ratio (TTM)

ALGS2.19x

ATNM4.08x

Quick Ratio (TTM)

ALGS2.19x

ATNM3.94x

Debt/Equity (TTM)

ALGS0.00x

ATNM0.00x

Debt/Assets (TTM)

ALGS0.0%

ATNM0.0%

Interest Coverage (TTM)

ALGSN/A

ATNMN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

ATNM0.00x

Beta

ALGS2.48

ATNM0.33

52W Performance

ALGS-46.2%

ATNM-28.6%

YTD Performance

ALGS-41.5%

ATNM-19.7%

% from 52W High

ALGS-61.0%

ATNM-36.8%

% from 52W Low

ALGS34.2%

ATNM49.6%

Asset Turnover (TTM)

ALGS0.38x

ATNM0.73x

FCF Yield (TTM)

ALGS-286.0%

ATNM-67.4%

Earnings Yield (TTM)

ALGS-229.8%

ATNM32.8%

Dividend Yield (TTM)

ALGSN/A

ATNMN/A

Rule of 40

ALGS593.1

ATNM-66.2

EV/GP/RG

ALGSN/A

ATNMN/A

Ticker research

View ALGS research View ATNM research

Metric	ALGS Aligos Therapeutics Inc	ATNM Actinium Pharmaceuticals Inc
Market & Valuation
Market Cap	$33M	$35M
Enterprise Value	$3M	$-2M
Price	$5.34	$1.10
P/E Ratio	N/A	3.06x
P/S Ratio	1.05x	0.98x
EV/Sales	0.09x	-0.06x
EV/EBITDA	0.00x	-0.20x
P/B Ratio	1.09x	1.21x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	0.08x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$35M
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	-0.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	62.3%
EBITDA Margin (TTM)	-247.2%	27.9%
Net Margin (TTM)	-241.0%	32.2%
FCF Margin (TTM)	-299.9%	-66.2%
Net Income (TTM)	$-76M	$11M
FCF (TTM)	$-95M	$-23M
EPS (TTM)	-$7.28	$0.36
ROE (TTM)	-16072.0%	83.4%
ROA (TTM)	-9230.0%	23.4%
ROIC (TTM)	-16035.0%	83.4%
Financial Health
Cash	$30M	$36M
Debt	$64K	$5K
Net Cash/Debt	$30M	$36M
Current Ratio (TTM)	2.19x	4.08x
Quick Ratio (TTM)	2.19x	3.94x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	0.33
52W Performance	-46.2%	-28.6%
YTD Performance	-41.5%	-19.7%
% from 52W High	-61.0%	-36.8%
% from 52W Low	34.2%	49.6%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.73x
FCF Yield (TTM)	-286.0%	-67.4%
Earnings Yield (TTM)	-229.8%	32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	-66.2
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View ATNM research

Valuation

P/E Ratio

ATNM

3.06x

P/S Ratio

ATNM

0.98x

ALGS

1.05x

EV/FCF

ALGS

-0.03x

ATNM

0.08x

Growth & revenue

Revenue Growth TTM

ALGS

893.0%

Forward Revenue Growth

ATNM

-0.2%

ALGS

-84.9%

Profitability & performance

Gross Margin

ALGS

0.0%

ATNM

0.0%

ROE

ATNM

83.4%

ALGS

-16072.0%

FCF Yield %

ATNM

-67.4%

ALGS

-286.0%

52-Week Performance

ATNM

-28.6%

ALGS

-46.2%

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

ATNM

Actinium Pharmaceuticals Inc

Market Cap

ALGS$33M

ATNM$35M

Enterprise Value

ALGS$3M

ATNM$-2M

Price

ALGS$5.34

ATNM$1.10

P/E Ratio

ALGSN/A

ATNM3.06x

P/S Ratio

ALGS1.05x

ATNM0.98x

EV/Sales

ALGS0.09x

ATNM-0.06x

EV/EBITDA

ALGS0.00x

ATNM-0.20x

P/B Ratio

ALGS1.09x

ATNM1.21x

P/FCF Ratio

ALGSN/A

ATNMN/A

EV/FCF

ALGS-0.03x

ATNM0.08x

PEG Ratio

ALGSN/A

ATNMN/A

Forward P/E (NTM)

ALGSN/A

ATNMN/A

Forward P/S (NTM)

ALGS4.83x

ATNMN/A

Revenue (TTM)

ALGS$32M

ATNM$35M

Revenue Growth (YoY)

ALGS893.0%

ATNMN/A

Forward Rev Growth

ALGS-84.9%

ATNM-0.2%

Gross Margin (TTM)

ALGS0.0%

ATNM0.0%

Operating Margin (TTM)

ALGS0.0%

ATNM62.3%

EBITDA Margin (TTM)

ALGS-247.2%

ATNM27.9%

Net Margin (TTM)

ALGS-241.0%

ATNM32.2%

FCF Margin (TTM)

ALGS-299.9%

ATNM-66.2%

Net Income (TTM)

ALGS$-76M

ATNM$11M

FCF (TTM)

ALGS$-95M

ATNM$-23M

EPS (TTM)

ALGS-$7.28

ATNM$0.36

ROE (TTM)

ALGS-16072.0%

ATNM83.4%

ROA (TTM)

ALGS-9230.0%

ATNM23.4%

ROIC (TTM)

ALGS-16035.0%

ATNM83.4%

Cash

ALGS$30M

ATNM$36M

Debt

ALGS$64K

ATNM$5K

Net Cash/Debt

ALGS$30M

ATNM$36M

Current Ratio (TTM)

ALGS2.19x

ATNM4.08x

Quick Ratio (TTM)

ALGS2.19x

ATNM3.94x

Debt/Equity (TTM)

ALGS0.00x

ATNM0.00x

Debt/Assets (TTM)

ALGS0.0%

ATNM0.0%

Interest Coverage (TTM)

ALGSN/A

ATNMN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

ATNM0.00x

Beta

ALGS2.48

ATNM0.33

52W Performance

ALGS-46.2%

ATNM-28.6%

YTD Performance

ALGS-41.5%

ATNM-19.7%

% from 52W High

ALGS-61.0%

ATNM-36.8%

% from 52W Low

ALGS34.2%

ATNM49.6%

Asset Turnover (TTM)

ALGS0.38x

ATNM0.73x

FCF Yield (TTM)

ALGS-286.0%

ATNM-67.4%

Earnings Yield (TTM)

ALGS-229.8%

ATNM32.8%

Dividend Yield (TTM)

ALGSN/A

ATNMN/A

Rule of 40

ALGS593.1

ATNM-66.2

EV/GP/RG

ALGSN/A

ATNMN/A

Ticker research

View ALGS research View ATNM research

Metric	ALGS Aligos Therapeutics Inc	ATNM Actinium Pharmaceuticals Inc
Market & Valuation
Market Cap	$33M	$35M
Enterprise Value	$3M	$-2M
Price	$5.34	$1.10
P/E Ratio	N/A	3.06x
P/S Ratio	1.05x	0.98x
EV/Sales	0.09x	-0.06x
EV/EBITDA	0.00x	-0.20x
P/B Ratio	1.09x	1.21x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	0.08x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$35M
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	-0.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	62.3%
EBITDA Margin (TTM)	-247.2%	27.9%
Net Margin (TTM)	-241.0%	32.2%
FCF Margin (TTM)	-299.9%	-66.2%
Net Income (TTM)	$-76M	$11M
FCF (TTM)	$-95M	$-23M
EPS (TTM)	-$7.28	$0.36
ROE (TTM)	-16072.0%	83.4%
ROA (TTM)	-9230.0%	23.4%
ROIC (TTM)	-16035.0%	83.4%
Financial Health
Cash	$30M	$36M
Debt	$64K	$5K
Net Cash/Debt	$30M	$36M
Current Ratio (TTM)	2.19x	4.08x
Quick Ratio (TTM)	2.19x	3.94x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	0.33
52W Performance	-46.2%	-28.6%
YTD Performance	-41.5%	-19.7%
% from 52W High	-61.0%	-36.8%
% from 52W Low	34.2%	49.6%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.73x
FCF Yield (TTM)	-286.0%	-67.4%
Earnings Yield (TTM)	-229.8%	32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	-66.2
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View ATNM research